Nature Medicine, Published online: 27 February 2026; doi:10.1038/s41591-025-04179-4
In a randomized trial enrolling 354 patients with heterozygous familial hypercholesterolemia on maximally tolerated lipid-lowering therapy, treatment with the cholesteryl ester transfer protein inhibitor obicetrapib was well tolerated and significantly lowered low-density lipoprotein cholesterol by 36.3% as compared to placebo.
